No connection

Search Results

Corporate Score 32 Neutral

MoonLake Immunotherapeutics CEO Sells $2.75 Million in Shares

Apr 18, 2026 14:37 UTC
MLTX
Short term

CEO Jorge Santos da Silva reduced his direct holdings in MoonLake Immunotherapeutics by approximately 4.9%. Despite the sale, the executive retains a significant stake in the clinical-stage biotech firm.

  • CEO sold 150,000 shares at an average price of $18.35
  • Total transaction value was approximately $2.75 million
  • CEO retains over 2.9 million shares, representing the bulk of his holdings
  • Sonelokimab therapy has been granted FDA fast track designation
  • Cash reserves were $394 million at the end of 2025
  • Quarterly operating expenses are approximately $65 million

Jorge Santos da Silva, CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX), has sold 150,000 shares of company stock through open-market transactions. The sales, executed on April 10 and 13, 2026, were completed at a weighted average price of $18.35 per share, totaling approximately $2.75 million. According to SEC Form 4 filings, the transaction represents a small fraction of the CEO's overall position. Following the sale, Santos da Silva continues to hold 2,924,893 shares directly, suggesting a continued long-term commitment to the company's trajectory despite the divestment. MoonLake is currently a clinical-stage entity focusing on inflammatory diseases using proprietary Nanobody technology. The company's primary asset, Sonelokimab, has received a fast track designation from the U.S. Food and Drug Administration (FDA), though the stock has faced pressure following previous clinical trial results and a decline from its 52-week high of $62.75. The company remains pre-revenue with quarterly operating expenses estimated at $65 million. However, MoonLake maintains a solid liquidity position, reporting $394 million in cash at the end of 2025. Investors continue to weigh the potential of FDA approval against the inherent risks of clinical-stage biotechnology investing.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 30

Ark Invest Deploys $2.5 Million Into Slumping Megacap Equity

Apr 18, 16:17

Score 62 Bullish

Apple Seizes Global Smartphone Leadership Amid Industry Contraction

Apr 18, 16:01

Score 32 Bullish

Rezolve AI Targets Aggressive Expansion Through Agentic Commerce and Strategic M&A

Apr 18, 15:35

Score 32

The Buckle EVP Divests $1.6 Million in Company Shares

Apr 18, 15:32

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile